Immunoglobulin D multiple myeloma

Response to therapy, survival, and prognostic factors in 75 patients

M. K. Kim, C. Suh, D. H. Lee, C. K. Min, S. J. Kim, K. Kim, J. H. Moon, S. S. Yoon, G. W. Lee, H. J. Kang, S. H. Kim, Chul Won Choi, H. S. Eom, J. Y. Kwak, H. J. Kim, Y. C. Mun, S. M. Bang, K. Lee, H. J. Shin, J. H. Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). Design and methods: Seventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr). Results: Median age was 57 years and the main presenting features were bone pain (77%). Renal function impairment and hypercalcemia were present in 40 (53%) and 20 (27%) patients. Sixty-seven patients (89%) had lambda light chains. Forty-eight patients (64%) were of stage III by International Staging System. Twenty-six patients (53%) had chromosomal abnormalities mostly by conventional cytogenetics. Thirty-nine patients (54%) were treated with vincristine, adriamycin, and dexamethasone chemotherapy; the overall response rate (ORR) of 56%. Sixteen patients (22%) received first-line chemotherapy including new drugs (bortezomib or thalidomide), with an ORR of 81%. At a median follow-up time of 28.6 months, median overall survival (OS) was 18.5 months. Age, extramedullary plasmacytoma, del(13) or hypoploidy, serum β2 microglobulin level, and platelet count were significant prognostic factors for OS. Conclusions: IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalAnnals of Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - 2011 Feb 2

Fingerprint

Immunoglobulin D
Multiple Myeloma
Survival
Therapeutics
Drug Therapy
Thalidomide
Plasmacytoma
Hypercalcemia
Stem Cell Transplantation
Vincristine
Platelet Count
Cytogenetics
Chromosome Aberrations
Doxorubicin
Dexamethasone
Registries
Databases
Kidney
Light
Bone and Bones

Keywords

  • Immunoglobulin D
  • Multiple myeloma
  • Treatment outcome

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Kim, M. K., Suh, C., Lee, D. H., Min, C. K., Kim, S. J., Kim, K., ... Lee, J. H. (2011). Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients. Annals of Oncology, 22(2), 411-416. https://doi.org/10.1093/annonc/mdq393

Immunoglobulin D multiple myeloma : Response to therapy, survival, and prognostic factors in 75 patients. / Kim, M. K.; Suh, C.; Lee, D. H.; Min, C. K.; Kim, S. J.; Kim, K.; Moon, J. H.; Yoon, S. S.; Lee, G. W.; Kang, H. J.; Kim, S. H.; Choi, Chul Won; Eom, H. S.; Kwak, J. Y.; Kim, H. J.; Mun, Y. C.; Bang, S. M.; Lee, K.; Shin, H. J.; Lee, J. H.

In: Annals of Oncology, Vol. 22, No. 2, 02.02.2011, p. 411-416.

Research output: Contribution to journalArticle

Kim, MK, Suh, C, Lee, DH, Min, CK, Kim, SJ, Kim, K, Moon, JH, Yoon, SS, Lee, GW, Kang, HJ, Kim, SH, Choi, CW, Eom, HS, Kwak, JY, Kim, HJ, Mun, YC, Bang, SM, Lee, K, Shin, HJ & Lee, JH 2011, 'Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients', Annals of Oncology, vol. 22, no. 2, pp. 411-416. https://doi.org/10.1093/annonc/mdq393
Kim, M. K. ; Suh, C. ; Lee, D. H. ; Min, C. K. ; Kim, S. J. ; Kim, K. ; Moon, J. H. ; Yoon, S. S. ; Lee, G. W. ; Kang, H. J. ; Kim, S. H. ; Choi, Chul Won ; Eom, H. S. ; Kwak, J. Y. ; Kim, H. J. ; Mun, Y. C. ; Bang, S. M. ; Lee, K. ; Shin, H. J. ; Lee, J. H. / Immunoglobulin D multiple myeloma : Response to therapy, survival, and prognostic factors in 75 patients. In: Annals of Oncology. 2011 ; Vol. 22, No. 2. pp. 411-416.
@article{5619e80891ec4bfc978493102f06e59b,
title = "Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients",
abstract = "Background: To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). Design and methods: Seventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr). Results: Median age was 57 years and the main presenting features were bone pain (77{\%}). Renal function impairment and hypercalcemia were present in 40 (53{\%}) and 20 (27{\%}) patients. Sixty-seven patients (89{\%}) had lambda light chains. Forty-eight patients (64{\%}) were of stage III by International Staging System. Twenty-six patients (53{\%}) had chromosomal abnormalities mostly by conventional cytogenetics. Thirty-nine patients (54{\%}) were treated with vincristine, adriamycin, and dexamethasone chemotherapy; the overall response rate (ORR) of 56{\%}. Sixteen patients (22{\%}) received first-line chemotherapy including new drugs (bortezomib or thalidomide), with an ORR of 81{\%}. At a median follow-up time of 28.6 months, median overall survival (OS) was 18.5 months. Age, extramedullary plasmacytoma, del(13) or hypoploidy, serum β2 microglobulin level, and platelet count were significant prognostic factors for OS. Conclusions: IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.",
keywords = "Immunoglobulin D, Multiple myeloma, Treatment outcome",
author = "Kim, {M. K.} and C. Suh and Lee, {D. H.} and Min, {C. K.} and Kim, {S. J.} and K. Kim and Moon, {J. H.} and Yoon, {S. S.} and Lee, {G. W.} and Kang, {H. J.} and Kim, {S. H.} and Choi, {Chul Won} and Eom, {H. S.} and Kwak, {J. Y.} and Kim, {H. J.} and Mun, {Y. C.} and Bang, {S. M.} and K. Lee and Shin, {H. J.} and Lee, {J. H.}",
year = "2011",
month = "2",
day = "2",
doi = "10.1093/annonc/mdq393",
language = "English",
volume = "22",
pages = "411--416",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Immunoglobulin D multiple myeloma

T2 - Response to therapy, survival, and prognostic factors in 75 patients

AU - Kim, M. K.

AU - Suh, C.

AU - Lee, D. H.

AU - Min, C. K.

AU - Kim, S. J.

AU - Kim, K.

AU - Moon, J. H.

AU - Yoon, S. S.

AU - Lee, G. W.

AU - Kang, H. J.

AU - Kim, S. H.

AU - Choi, Chul Won

AU - Eom, H. S.

AU - Kwak, J. Y.

AU - Kim, H. J.

AU - Mun, Y. C.

AU - Bang, S. M.

AU - Lee, K.

AU - Shin, H. J.

AU - Lee, J. H.

PY - 2011/2/2

Y1 - 2011/2/2

N2 - Background: To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). Design and methods: Seventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr). Results: Median age was 57 years and the main presenting features were bone pain (77%). Renal function impairment and hypercalcemia were present in 40 (53%) and 20 (27%) patients. Sixty-seven patients (89%) had lambda light chains. Forty-eight patients (64%) were of stage III by International Staging System. Twenty-six patients (53%) had chromosomal abnormalities mostly by conventional cytogenetics. Thirty-nine patients (54%) were treated with vincristine, adriamycin, and dexamethasone chemotherapy; the overall response rate (ORR) of 56%. Sixteen patients (22%) received first-line chemotherapy including new drugs (bortezomib or thalidomide), with an ORR of 81%. At a median follow-up time of 28.6 months, median overall survival (OS) was 18.5 months. Age, extramedullary plasmacytoma, del(13) or hypoploidy, serum β2 microglobulin level, and platelet count were significant prognostic factors for OS. Conclusions: IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.

AB - Background: To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). Design and methods: Seventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr). Results: Median age was 57 years and the main presenting features were bone pain (77%). Renal function impairment and hypercalcemia were present in 40 (53%) and 20 (27%) patients. Sixty-seven patients (89%) had lambda light chains. Forty-eight patients (64%) were of stage III by International Staging System. Twenty-six patients (53%) had chromosomal abnormalities mostly by conventional cytogenetics. Thirty-nine patients (54%) were treated with vincristine, adriamycin, and dexamethasone chemotherapy; the overall response rate (ORR) of 56%. Sixteen patients (22%) received first-line chemotherapy including new drugs (bortezomib or thalidomide), with an ORR of 81%. At a median follow-up time of 28.6 months, median overall survival (OS) was 18.5 months. Age, extramedullary plasmacytoma, del(13) or hypoploidy, serum β2 microglobulin level, and platelet count were significant prognostic factors for OS. Conclusions: IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.

KW - Immunoglobulin D

KW - Multiple myeloma

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=79251592569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251592569&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq393

DO - 10.1093/annonc/mdq393

M3 - Article

VL - 22

SP - 411

EP - 416

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -